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In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, de Boer et al propose that human CD34 ϩ /KDR ϩ cells are generated from circulating CD34 ϩ cells after immobilization on activated platelets. 2 By using an ex vivo flow model, the authors show that activated platelets favor the homing of CD34 ϩ cells to sites of vascular injury and that, on cell immobilization, KDR is rapidly translocated from an endosomal compartment to the cell surface. Presumably, PCs shed afterward to "carry the message" into the circulation. It is noteworthy that de Boer et al also report an increased coexpression of KDR on CD34 ϩ cells in type-2 diabetes, which was reduced by aspirin treatment. The authors conclude that their data might have implications for the identification of patients with subclinical vascular injury, on the basis of the hypothesis that activated/injured endothelium provides more opportunity for platelet-CD34 ϩ PC interaction.
The analysis of the PC antigenic profile could represent an attractive means by which to verify the status of vascular health and monitor the progression of vascular disease. In fact, different PC readouts from a patient's blood sample might hint at distinct adaptive responses to specific environmental cues from the peripheral vasculature. The appropriate interpretation of such complex phenomena is hindered in part by current limitations in the standardization of flow cytometry analysis, leading to large variations in the absolute and relative expression of surface antigens. In their study, de Boer et al apply state-of-the-art technology, including the use of counting beads (for the acquisition of absolute numbers of cells per volume of blood) and a multiparametric gating strategy based on the International Society of Hematotherapy and Graft Engineering protocol. Using a similar strategy, Schmidt-Lucke et al have recently shown that CD45 dim CD34 ϩ KDR ϩ PCs correlate inversely with the grade of coronary artery disease and are increased by statin treatment, thereby possibly serving as a biomarker of endothelial status. 3 One puzzling aspect of the study by de Boer et al is represented by the remarkably low levels of KDR expression on the surface of CD34 ϩ cells from healthy controls. Although KDR was found to be variably expressed, previous reports showed values 10-fold higher than the figure reported in de Boer's study. Furthermore, a large body of evidence indicates a reduction rather than an increase in KDR expression in diabetes. [3] [4] [5] A recent metaanalysis of 4 longitudinal studies including 1,057 patients showed that low abundance of CD34 ϩ KDR ϩ PCs is associated with a higher risk of major adverse cardiovascular events. 6 On the other hand, we found that in type-1 diabetic patients free from cardiovascular complications except mild background retinopathy, the number of circulating CD34 ϩ KDR ϩ PCs is similar to that of age-matched controls; nevertheless, functional deficits were detected in the fraction of diabetic cells that migrate toward a chemoattractant. 7 Thus, functional analysis might provide useful information at an early stage, before the antigenic profile becomes altered. One possible explanation for the apparent discrepancy in KDR ϩ counts is that pharmacological treatment can confound the final readout. However, apart from statin and aspirin, common cardiovascular drugs reportedly do not have an influence on CD34 ϩ KDR ϩ numbers. 8 Another aspect, the resistance to VEGF signals in diabetes, was recently studied by Tchaikovski et al in monocytes. 9 Because of the preactivation of intracellular signaling pathways in cells derived from diabetic donors, VEGF was unable to induce further specific cellular activation. Directly equating cell function with KDR expression on CD34 ϩ PCs might therefore be misleading.
The proposal that cellular interaction induces KDR surface expression on CD34 ϩ cells raises further questions (Figure) . If CD34 ϩ KDR ϩ cells are more adhesive than CD34 ϩ KDR Ϫ cells, why are the former augmented in the circulation of diabetic patients rather than remaining adherent to the vessel wall? In a broader context, can detached PCs carry messages from tissues and the vessel wall back to the circulation and finally the bone marrow (BM)? Are adhering/circulating cells in dynamic equilibrium with cells continuously released from the BM? To enter the circulation, BM cells have to pass the endothelial sinusoid barrier. Is this an additional site for KDR induction on transmigrating cells? The authors show that the abundance of KDR ϩ on CD34 ϩ cells does not increase after active mobilization with granulocyte colony-stimulating factor, which is supportive of KDR being a peripheral addendum. However, granulocyte colony-stimulating factorinduced mobilization could be rapid enough to minimize KDR translocation on CD34 ϩ cell surface during transendothelial migration. A recent study from our group showed an increased adhesion of BM-derived PCs to diabetic BM endothelial cells under static conditions and after introduction of shear flow. 10 This enhanced adhesive contact may facilitate the acquisition of endothelial antigens like KDR by transmigrating CD34 ϩ cells. It would be relevant to investigate whether aspirin treatment results in a more rapid transmigration of KDR Ϫ PCs into the circulation.
Furthermore, alternative mechanisms might also explain the presence of KDR on adhering CD34 ϩ PC surface. It was proposed that platelet-derived microparticles start to cover PCs immediately after their entry into the bloodstream from the BM and thereby enhance the adhesive capacities of PCs. 11 Putative endothelial markers, such as CD31 and von Willebrand factor, are also abundant on platelets. In addition, platelets contain cryptic VEGF receptors, including KDR, which become exposed on the platelet membrane following stimulation by VEGF. It is therefore possible that, as shown for other endothelial antigens, KDR is exchanged from platelets to adherent PCs. 12 Finally, transcription factors, small molecules, and microRNAs could be delivered during transient or firm interactions with the endothelium, thereby inducing specific responses, including expression of surface antigens, in target cells. 13 The capacity of recipient cells to selectively elaborate the donated material suggests that these are close encounters that leave a sign. (1) Can BM cells acquire KDR while passing the vascular sinusoid barrier to reach the circulation? (2) Can endothelial-associated transcription factors and microRNAs, among other factors, deliver messages that induce KDR expression? (3) Can platelet-derived KDR be transferred to CD34 ϩ cells? (4) If CD34 ϩ /KDR ϩ cells firmly adhere to the activation site, why they are found augmented in diabetes? (5) Can CD34 ϩ /KDR ϩ cells carry messages back to the BM? (6) Are cells in dynamic equilibrium between circulation and BM? (7) Does the analysis of the circulating cells truly reflect what is happening at the vascular level?
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